CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 236 enrolled
Drug / intervention
Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00798759
NCT00798759Phase 4Completed
CompareCT.gov

Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN®

Alcon Research·interventional·Posted Nov 26, 2008·Updated Jun 1, 2012

In Brief

A Phase 4 clinical trial evaluating Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) and Latanoprost ophthalmic solution 0.005% (XALATAN®) for Open-angle Glaucoma and Ocular Hypertension. Completed, enrolled 236 participants.

Detailed Summary

The purpose of this study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 26, 2008
Enrollment StartDec 1, 2008
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.6 years ago

Interventions

Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)drug

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.

Latanoprost ophthalmic solution 0.005% (XALATAN®)drug

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.